Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Zika Virus Infection
4.2.2 Increasing R&D by Biopharmaceutical Companies
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Cost of Testing Kits
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Molecular Test
5.1.2 Serologic Test
5.2 By End User
5.2.1 Hospital/Clinic
5.2.2 Diagnostics Laboratory
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Altona Diagnostics GmbH
6.1.3 Chembio Diagnostic Systems Inc.
6.1.4 ELITechGroup
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Genekam
6.1.7 Luminex Corporation
6.1.8 Novacyt Group
6.1.9 Quest Diagnostics
6.1.10 Siemens AG


7 MARKET OPPORTUNITIES AND FUTURE TRENDS